TuHURA Biosciences Stockholders Approve Directors, Parkview Share Issuance at Annual Meeting

TuHURA Biosciences (NASDAQ:HURA) stockholders approved all substantive proposals presented at the company’s 2026 annual meeting, including the election of six directors, a share issuance related to its revolving credit facility and advisory votes on executive compensation.

The virtual meeting was chaired by President and CEO Dr. Jim Bianco, who said the company’s notice of meeting and proxy statement were filed with the Securities and Exchange Commission and distributed to stockholders on or about July 9, 2026.

Maritza Merced, TuHURA’s Inspector of Election, reported that June 26, 2026, was the meeting’s record date. The company had 63,682,528 common shares outstanding as of that date, and proxies representing at least one-third of the voting power of shares entitled to vote had been received, establishing a quorum.

Director Elections Approved

Stockholders approved the election of six directors to serve until the 2027 annual meeting and until their successors are elected and qualified, or until earlier death, resignation or removal. The elected nominees were:

• James Bianco
• James Manuso
• Alan List
• George Ng
• Robert Hoffman
• Craig Tendler

Merced said each nominee was approved by a plurality of votes cast.

Parkview Share Issuance Receives Stockholder Approval

Stockholders also approved, under Nasdaq Listing Rule 5635, the issuance of 1,878,287 shares of TuHURA common stock to Parkview Holdings One LLC. Parkview is an affiliate of Vijay Patel, whom Bianco identified as the company’s largest shareholder.

The shares are issuable under the terms of TuHURA’s revolving credit facility with Parkview, which the company entered into in April 2026. The Nasdaq proposal was approved by a majority of votes cast.

Executive Compensation and Auditor Matters

Stockholders approved an advisory, non-binding proposal on compensation for TuHURA’s named executive officers. They also supported the board’s recommended frequency for future advisory votes on named executive officer compensation: every three years.

Merced said the every-three-years option received the highest number of votes cast in the say-on-frequency proposal.

In addition, stockholders ratified the appointment of Cherry Bekaert LLP as TuHURA’s independent registered public accounting firm for the fiscal year ending Dec. 31, 2026.

Because the other proposals were approved, the company said there was no need to vote on the proposal that would have allowed an adjournment of the annual meeting to a later date or time if necessary.

Bianco said the company will disclose the final tabulation for each proposal in a Form 8-K filing with the SEC within four business days. The meeting was then adjourned.

About TuHURA Biosciences (NASDAQ:HURA)

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.